<code id='E5D85C0875'></code><style id='E5D85C0875'></style>
    • <acronym id='E5D85C0875'></acronym>
      <center id='E5D85C0875'><center id='E5D85C0875'><tfoot id='E5D85C0875'></tfoot></center><abbr id='E5D85C0875'><dir id='E5D85C0875'><tfoot id='E5D85C0875'></tfoot><noframes id='E5D85C0875'>

    • <optgroup id='E5D85C0875'><strike id='E5D85C0875'><sup id='E5D85C0875'></sup></strike><code id='E5D85C0875'></code></optgroup>
        1. <b id='E5D85C0875'><label id='E5D85C0875'><select id='E5D85C0875'><dt id='E5D85C0875'><span id='E5D85C0875'></span></dt></select></label></b><u id='E5D85C0875'></u>
          <i id='E5D85C0875'><strike id='E5D85C0875'><tt id='E5D85C0875'><pre id='E5D85C0875'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:96

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia